NCT05763706 Photobiomodulation Therapy in the Management of Chemotherapy-Induced Peripheral Neuropathy
| NCT ID | NCT05763706 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Jessa Hospital |
| Condition | Chemotherapy-induced Peripheral Neuropathy |
| Study Type | INTERVENTIONAL |
| Enrollment | 172 participants |
| Start Date | 2023-03-27 |
| Primary Completion | 2025-03-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 172 participants in total. It began in 2023-03-27 with a primary completion date of 2025-03-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to investigate the effectiveness of photobiomodulation therapy (PBM) in the management of chemotherapy-induced peripheral neuropathy (CIPN). Therefore, the hypothesis is that PBM can reduce the severity of CIPN in cancer patients, increasing the patient's quality of life.
Eligibility Criteria
Inclusion Criteria: * Finished one of the following types of chemotherapy: paclitaxel, docetaxel, oxaliplatin, cisplatin, vincristine, thalidomide and/or bortezomib. * Diagnosed with CIPN * Age 18 years or above * Have no documented or observable psychiatric or neurological disorders that might interfere with study participation (e.g., dementia or psychosis) * Dutch-speaking * Signed informed consent Exclusion Criteria: * Taking stable doses of medication on prescription for peripheral neuropathy. Related medications are: gabapentin, pregabalin (Lyrica), nortriptyline, amitriptyline, duloxetine (Cymbalta), and venlafaxine. * Severe or unstable cardio- respiratory or musculoskeletal disease * Interruption of more than two consecutive laser treatments * Dark brown or black skin pigmentation (described as skin type VI in the Fitzpatrick scale)
Contact & Investigator
Jeroen mebis, Prof. Dr.
PRINCIPAL INVESTIGATOR
Jessa Hospital
Frequently Asked Questions
Who can join the NCT05763706 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Chemotherapy-induced Peripheral Neuropathy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05763706 currently recruiting?
Yes, NCT05763706 is actively recruiting participants. Contact the research team at jeroen.mebis@jessazh.be for enrollment information.
Where is the NCT05763706 trial being conducted?
This trial is being conducted at Hasselt, Belgium.
Who is sponsoring the NCT05763706 clinical trial?
NCT05763706 is sponsored by Jessa Hospital. The principal investigator is Jeroen mebis, Prof. Dr. at Jessa Hospital. The trial plans to enroll 172 participants.